Materiały źródłowe

• #1 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  Psoriatic arthritis (PsA) is a chronic, progressive inflammatory arthritis that is common among patients with psoriasis and may result in permanent joint damage and disability. […] We now know that PsA is a systemic inflammatory disorder with health consequences beyond joint function such as cardiovascular disease and similar outcomes to rheumatoid arthritis (RA) including the prevalence of erosions and joint destruction. […] Development of more uniformly accepted classification criteria in 2006 have allowed for more comparable populations among epidemiologic studies. […] In this review, we discuss current knowledge around the epidemiology of psoriatic arthritis including prevalence of disease characteristics, classification of adult and pediatric psoriatic arthritis, the importance of early diagnosis of PsA including methods for screening and knowledge regarding risk factors for the development of PsA.

• #2 The epidemiology and risk of mortality for patients with psoriatic arthritis

  https://psoriasis-hub.com/medical-information/the-epidemiology-and-risk-of-mortality-for-patients-with-psoriatic-arthritis

  In the general population, the prevalence of psoriatic arthritis (PsA) ranges from 0.1% to 1% worldwide. A high degree of variability has been observed between epidemiological studies, partly due to the geographic location and due to the use of different definitions of PsA. […] Most studies of prevalence trends of PsA have shown an increase in recent years. […] The prevalence of PsA in patients with psoriasis has been shown to be variable between continents: Asia, 14.0%; Africa, 15.5%; North America, 19.5%; South America, 21.5%; Europe, 22.7%. […] The incidence of PsA among patients with psoriasis is also varied, ranging from 1.7% to 7.4%. […] Evidence regarding the impact of PsA on mortality is conflicting, with the standardized mortality rate (SMR) varying from 0.05 to 98.5. […] Overall mortality does not appear to be increased in patients with PsA; however, there is an increase in certain cause-specific mortality groups such as cardiovascular comorbidities.

• #3 Psoriatic arthritis: epidemiology, clinical features, course, and outcome | Annals of the Rheumatic Diseases

  https://bibliotheek.ehb.be:2673/content/64/suppl_2/ii14

  Psoriatic arthritis (PsA) has been defined as a unique inflammatory arthritis associated with psoriasis. Its exact prevalence is unknown, but estimates vary from 0.3% to 1% of the population. […] The exact prevalence of PsA is unknown and its estimation has been difficult, partly due to the lack of a widely accepted classification or diagnostic criteria, and partly due to the fact that even experts may fail to make the correct diagnosis. Estimated prevalence rates vary from 0.04% in the Faroe Islands to 0.1% in a study from the Mayo Clinic. The reported incidence of PsA has varied from 3.4 to 8 per 100000.79 It may very well be that these are underestimates. […] A recent study from Sweden suggests that PsA occurs in 30% of patients with psoriasis. Similarly a study of patients attending a psoriasis clinic identified 31% as having PsA. If this prevalence is correct, the prevalence of PsA in the general population should be close to 1%. Once the Classification of Psoriatic Arthritis (CASPAR) group arrives at a valid set of diagnostic/classification criteria, a proper prospective epidemiological study can be performed to determine accurately the prevalence of the disease.

• #4 The epidemiology and risk of mortality for patients with psoriatic arthritis

  https://psoriasis-hub.com/medical-information/the-epidemiology-and-risk-of-mortality-for-patients-with-psoriatic-arthritis

  In the general population, the prevalence of psoriatic arthritis (PsA) ranges from 0.1% to 1% worldwide. A high degree of variability has been observed between epidemiological studies, partly due to the geographic location and due to the use of different definitions of PsA. […] Most studies of prevalence trends of PsA have shown an increase in recent years. […] The prevalence of PsA in patients with psoriasis has been shown to be variable between continents: Asia, 14.0%; Africa, 15.5%; North America, 19.5%; South America, 21.5%; Europe, 22.7%. […] The incidence of PsA among patients with psoriasis is also varied, ranging from 1.7% to 7.4%. […] Evidence regarding the impact of PsA on mortality is conflicting, with the standardized mortality rate (SMR) varying from 0.05 to 98.5. […] Overall mortality does not appear to be increased in patients with PsA; however, there is an increase in certain cause-specific mortality groups such as cardiovascular comorbidities.

• #5 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  A number of studies have examined prevalence of PsA in countries all over the world. […] Prevalence estimates in the United States range from 0.060.25% with the lowest estimate derived from a paper that utilized International Classification of Disease ninth edition (ICD-9) codes to identify cases and the highest from articles using patient self-report of diagnosis of PsA. […] Prevalence estimates in Europe range from 0.05% in Turkey and the Czech Republic to 0.21% in Sweden. […] The incidence of PsA in the general population has been examined by relatively few studies. […] The reported incidence of PsA in recent publications ranges from 3.67.2 per 100,000 person years. […] While PsA has a low prevalence in the general population, it is common among patients with psoriasis. […] Again, prevalence estimates vary considerably (range 6%41%) depending on the definitions used (i.e. diagnostic codes, rheumatologist diagnosis, classification criteria, diagnostic codes, and the populations measured.

• #6 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  A number of studies have examined prevalence of PsA in countries all over the world. […] Prevalence estimates in the United States range from 0.060.25% with the lowest estimate derived from a paper that utilized International Classification of Disease ninth edition (ICD-9) codes to identify cases and the highest from articles using patient self-report of diagnosis of PsA. […] Prevalence estimates in Europe range from 0.05% in Turkey and the Czech Republic to 0.21% in Sweden. […] The incidence of PsA in the general population has been examined by relatively few studies. […] The reported incidence of PsA in recent publications ranges from 3.67.2 per 100,000 person years. […] While PsA has a low prevalence in the general population, it is common among patients with psoriasis. […] Again, prevalence estimates vary considerably (range 6%41%) depending on the definitions used (i.e. diagnostic codes, rheumatologist diagnosis, classification criteria, diagnostic codes, and the populations measured.

• #7 Psoriatic Arthritis: Practice Essentials, Background, Pathophysiology and Etiology

  https://emedicine.medscape.com/article/2196539-overview

  A systematic review and meta-analysis of 28 studies estimated that the global average prevalence of psoriatic arthritis is 133 per 100,000 population (95% confidence interval [CI], 107-164 per 100,000), and the incidence is 83 per 100,000 persons per year (95% CI, 41-167 per 100,000). A systematic review and meta-analysis of 266 studies concluded that worldwide, approximately one in four persons with psoriasis has psoriatic arthritis. However, the prevalence of psoriatic arthritis internationally ranges widely, depending on the population studied. A 2013 German study found the rate of psoriatic arthritis in patients with psoriasis to be 30.2%. […] […] In a prospective cohort study from Canada that involved psoriasis patients without arthritis at study entry, 51 of 464 patients developed psoriatic arthritis over the course of 8 years of follow-up. The annual incidence rate was 2.7 cases of psoriatic arthritis per 100 psoriasis patients. Baseline variables associated with the development of psoriatic arthritis in multivariate analysis included the following: severe psoriasis (relative risk [RR] 5.4, P = 0.006); low level of education (college/university vs. high school incomplete, RR 4.5, P = 0.005; high school education vs high school incomplete, RR 3.3, P = 0.049); use of retinoid medications (RR 3.4, P = 0.02). […]

• #8 Epidemiological trends in psoriatic arthritis: a comprehensive population-based study | Arthritis Research & Therapy | Full Text

  https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-024-03339-0

  The reported prevalence of PsA worldwide ranges from 0.1 to 1% in the general population. […] Most investigations into PsA prevalence trends indicate a rise in prevalence in recent years, whereas fewer studies addressing incidence trends over time yield inconsistent findings. […] The objectives of our study encompassed estimating the temporal trends in PsA prevalence and incidence, as well as assessing variations among different age, gender, and ethnic subgroups in the general population of Israel spanning from 2016 to 2022. […] The crude prevalence of PsA has increased during the study period, from 0.165% in 2016 to 0.221% in 2022 and compared to 2006, it had tripled. […] The prevalence of PsA was associated with several demographic and lifestyle factors. […] Our study demonstrates an increasing trend in the crude and age-adjusted prevalence and incidence of PsA over the study period.

• #9 Psoriatic Arthritis: Practice Essentials, Background, Pathophysiology and Etiology

  https://emedicine.medscape.com/article/2196539-overview

  According to the National Psoriasis Foundation, psoriatic arthritis affects about 1 million people in the United States, or about 30% of all persons with psoriasis. However, prevalence rates vary widely among studies. In one population-based study, less than 10% of patients with psoriasis developed clinically recognized psoriatic arthritis during a 30-year period. A random telephone survey of 27,220 US residents found a 0.25% prevalence rate for psoriatic arthritis in the general population and an 11% prevalence rate in patients with psoriasis. However, the exact frequency of the disorder in patients with psoriasis remains uncertain, with the estimated rate ranging from 5-30%. […] […] Moreover, since the late 20th century, the incidence of psoriatic arthritis appears to have been rising in both men and women. Reasons for the increase are unknown; it may be related to a true change in incidence or to a greater overall awareness of the diagnosis by physicians. […]

• #10 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  A number of studies have examined prevalence of PsA in countries all over the world. […] Prevalence estimates in the United States range from 0.060.25% with the lowest estimate derived from a paper that utilized International Classification of Disease ninth edition (ICD-9) codes to identify cases and the highest from articles using patient self-report of diagnosis of PsA. […] Prevalence estimates in Europe range from 0.05% in Turkey and the Czech Republic to 0.21% in Sweden. […] The incidence of PsA in the general population has been examined by relatively few studies. […] The reported incidence of PsA in recent publications ranges from 3.67.2 per 100,000 person years. […] While PsA has a low prevalence in the general population, it is common among patients with psoriasis. […] Again, prevalence estimates vary considerably (range 6%41%) depending on the definitions used (i.e. diagnostic codes, rheumatologist diagnosis, classification criteria, diagnostic codes, and the populations measured.

• #11 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  A number of studies have examined prevalence of PsA in countries all over the world. […] Prevalence estimates in the United States range from 0.060.25% with the lowest estimate derived from a paper that utilized International Classification of Disease ninth edition (ICD-9) codes to identify cases and the highest from articles using patient self-report of diagnosis of PsA. […] Prevalence estimates in Europe range from 0.05% in Turkey and the Czech Republic to 0.21% in Sweden. […] The incidence of PsA in the general population has been examined by relatively few studies. […] The reported incidence of PsA in recent publications ranges from 3.67.2 per 100,000 person years. […] While PsA has a low prevalence in the general population, it is common among patients with psoriasis. […] Again, prevalence estimates vary considerably (range 6%41%) depending on the definitions used (i.e. diagnostic codes, rheumatologist diagnosis, classification criteria, diagnostic codes, and the populations measured.

• #12 Clinical manifestations and diagnosis of psoriatic arthritis – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-psoriatic-arthritis

  Psoriatic arthritis (PsA) affects females and males equally, with an incidence of approximately 6 per 100,000 per year and a prevalence of approximately 1 to 2 per 1000 in the general population. […] A Canadian population study from 2019 reported the cumulative prevalence estimate for PsA of 0.17 percent, with an incidence of 15 per 100,000 population. […] A 2019 meta-analysis described an overall pooled prevalence of PsA of 20 percent in patients with psoriasis and 25 percent in the subset with moderate to severe psoriasis. […] Estimates of the prevalence of PsA among patients with psoriasis have ranged from 4 to 30 percent. […] Estimates of the prevalence of PsA among patients with psoriasis range from 14 to 31 percent. […] A prospective study of patients who presented with psoriasis but no arthritis, followed annually, found the annual incidence of PsA to be 2.7 to 3.2 percent.

• #13 The epidemiology and risk of mortality for patients with psoriatic arthritis

  https://psoriasis-hub.com/medical-information/the-epidemiology-and-risk-of-mortality-for-patients-with-psoriatic-arthritis

  In the general population, the prevalence of psoriatic arthritis (PsA) ranges from 0.1% to 1% worldwide. A high degree of variability has been observed between epidemiological studies, partly due to the geographic location and due to the use of different definitions of PsA. […] Most studies of prevalence trends of PsA have shown an increase in recent years. […] The prevalence of PsA in patients with psoriasis has been shown to be variable between continents: Asia, 14.0%; Africa, 15.5%; North America, 19.5%; South America, 21.5%; Europe, 22.7%. […] The incidence of PsA among patients with psoriasis is also varied, ranging from 1.7% to 7.4%. […] Evidence regarding the impact of PsA on mortality is conflicting, with the standardized mortality rate (SMR) varying from 0.05 to 98.5. […] Overall mortality does not appear to be increased in patients with PsA; however, there is an increase in certain cause-specific mortality groups such as cardiovascular comorbidities.

• #14 The epidemiology and risk of mortality for patients with psoriatic arthritis

  https://psoriasis-hub.com/medical-information/the-epidemiology-and-risk-of-mortality-for-patients-with-psoriatic-arthritis

  In the general population, the prevalence of psoriatic arthritis (PsA) ranges from 0.1% to 1% worldwide. A high degree of variability has been observed between epidemiological studies, partly due to the geographic location and due to the use of different definitions of PsA. […] Most studies of prevalence trends of PsA have shown an increase in recent years. […] The prevalence of PsA in patients with psoriasis has been shown to be variable between continents: Asia, 14.0%; Africa, 15.5%; North America, 19.5%; South America, 21.5%; Europe, 22.7%. […] The incidence of PsA among patients with psoriasis is also varied, ranging from 1.7% to 7.4%. […] Evidence regarding the impact of PsA on mortality is conflicting, with the standardized mortality rate (SMR) varying from 0.05 to 98.5. […] Overall mortality does not appear to be increased in patients with PsA; however, there is an increase in certain cause-specific mortality groups such as cardiovascular comorbidities.

• #15 Psoriatic Arthritis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK547710/

  A literature review of the epidemiology of psoriatic arthritis showed the worldwide prevalence of psoriatic arthritis ranges from 0.1% to 1%. […] The prevalence of psoriatic arthritis in patients with psoriasis is 19.7%, with 21.6% in adults and 3.3% in children. […] The proportion of patients with psoriasis with psoriatic arthritis varies depending on the geography and ethnicity of the target population, with 22.7% in Europe, 19.5% in North America, 21.5% in South America, 15.5% in Africa, and 14% in Asia.

• #16

  https://link.springer.com/article/10.1007/s13671-012-0032-8

  Estimates of the prevalence of PsA among patients with psoriasis have varied from 6-39 %. […] The highest estimates of PsA among patients with psoriasis are generally derived from dermatology clinics, possibly due to the increased severity of psoriasis in the dermatology clinic relative to the general population. […] Risk factors for the development of PsA may help to identify patients with psoriasis who should be screened for PsA or watched carefully for the development of joint symptoms. […] Several noteworthy studies have addressed risk factors for PsA and have suggested that psoriasis severity, nail dystrophy, smoking, trauma, obesity, obesity at the age of 18 years, and prior glucocorticoid use are risk factors for PsA. […] Whereas dermatologists will have varying comfort in assessing for PsA, simple screening tools have been developed to help identify which patients should receive further evaluation for the diagnosis of PsA. […] Four screening tools have been developed to date: the Psoriasis Epidemiology Screening Tool (PEST), Toronto Psoriatic Arthritis Screening (ToPAS), Psoriasis and Arthritis Screening Questionnaire (PASQ), and Psoriatic Arthritis Screening and Evaluation (PASE). […] It is important to recognize that these screening questionnaires, while they can be helpful, have been found to have much lower sensitivity and specificity than those reported in the initial validation studies, particularly when applied among psoriasis patients without known PsA.

• #17 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  Studies examining the prevalence of PsA among patients with psoriasis have found that underdiagnosis is common. […] PsA is a clinically heterogeneous disorder. […] Classification criteria are designed to create more homogenous populations for research. […] The CASPAR criteria are the most widely used criteria and their high sensitivity and specificity (both 90% or better in most studies but sensitivity as low as 77.3% in D’Angelo et al 2009) have been demonstrated in many settings including dermatology and rheumatology clinics, family practice clinics, and among early arthritis cohorts. […] Early PsA is generally considered within the first two years of symptom onset. […] Increasing evidence supports the early diagnosis and treatment of PsA in order to improve long term outcomes. […] Knowledge of risk factors for PsA and use of screening tools may improve recognition of PsA among patients with psoriasis.

• #18 Psoriatic Arthritis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK547710/

  Psoriatic arthritis, occurring in approximately 20% of individuals with psoriasis, is a chronic inflammatory arthritis intricately linked to psoriatic arthritis. […] This course aims to address the reported 15% underdiagnosis rate, stressing the rising prevalence and the critical role of interprofessional collaboration in navigating the complexities of psoriatic arthritis. […] The epidemiology of psoriatic arthritis is heterogeneous and varies widely among various population groups. This condition has been estimated to have a prevalence of 0.05% to 0.25% in the general population and around 6% to 41% in patients with psoriasis. […] A meta-analysis showed the prevalence of undiagnosed psoriatic arthritis might be as high as 15.5%. […] The onset of psoriatic arthritis is usually seen in patients in their 30s and 40s and occurs about equally in men and women.

• #19 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  A number of studies have examined prevalence of PsA in countries all over the world. […] Prevalence estimates in the United States range from 0.060.25% with the lowest estimate derived from a paper that utilized International Classification of Disease ninth edition (ICD-9) codes to identify cases and the highest from articles using patient self-report of diagnosis of PsA. […] Prevalence estimates in Europe range from 0.05% in Turkey and the Czech Republic to 0.21% in Sweden. […] The incidence of PsA in the general population has been examined by relatively few studies. […] The reported incidence of PsA in recent publications ranges from 3.67.2 per 100,000 person years. […] While PsA has a low prevalence in the general population, it is common among patients with psoriasis. […] Again, prevalence estimates vary considerably (range 6%41%) depending on the definitions used (i.e. diagnostic codes, rheumatologist diagnosis, classification criteria, diagnostic codes, and the populations measured.

• #20 Psoriatic Arthritis: Practice Essentials, Background, Pathophysiology and Etiology

  https://emedicine.medscape.com/article/2196539-overview

  A systematic review and meta-analysis of 28 studies estimated that the global average prevalence of psoriatic arthritis is 133 per 100,000 population (95% confidence interval [CI], 107-164 per 100,000), and the incidence is 83 per 100,000 persons per year (95% CI, 41-167 per 100,000). A systematic review and meta-analysis of 266 studies concluded that worldwide, approximately one in four persons with psoriasis has psoriatic arthritis. However, the prevalence of psoriatic arthritis internationally ranges widely, depending on the population studied. A 2013 German study found the rate of psoriatic arthritis in patients with psoriasis to be 30.2%. […] […] In a prospective cohort study from Canada that involved psoriasis patients without arthritis at study entry, 51 of 464 patients developed psoriatic arthritis over the course of 8 years of follow-up. The annual incidence rate was 2.7 cases of psoriatic arthritis per 100 psoriasis patients. Baseline variables associated with the development of psoriatic arthritis in multivariate analysis included the following: severe psoriasis (relative risk [RR] 5.4, P = 0.006); low level of education (college/university vs. high school incomplete, RR 4.5, P = 0.005; high school education vs high school incomplete, RR 3.3, P = 0.049); use of retinoid medications (RR 3.4, P = 0.02). […]

• #21 Epidemiological trends in psoriatic arthritis: a comprehensive population-based study | Arthritis Research & Therapy | Full Text

  https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-024-03339-0

  Psoriatic arthritis (PsA) is a chronic, potentially debilitating inflammatory arthritis often associated with psoriasis. Understanding the epidemiology of PsA across diverse populations can provide valuable insights into its global burden and the role of genetic and environmental factors. This study aimed to estimate PsAs temporal trends, prevalence, and incidence, while assessing variations in age, gender, and ethnicity in Israel from 2016 to 2022. […] In 2022, the prevalence of PsA was 0.221%, with an incidence rate of 13.54 per 100,000 population. This prevalence has tripled since 2006, reflecting a rising trend in PsA over time. […] This comprehensive population-based study pointed to an increase prevalence of PsA, emphasizing the rising healthcare demands and economic burden faced by this patient population.

• #22 Clinical manifestations and diagnosis of psoriatic arthritis – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-psoriatic-arthritis

  Psoriatic arthritis (PsA) affects females and males equally, with an incidence of approximately 6 per 100,000 per year and a prevalence of approximately 1 to 2 per 1000 in the general population. […] A Canadian population study from 2019 reported the cumulative prevalence estimate for PsA of 0.17 percent, with an incidence of 15 per 100,000 population. […] A 2019 meta-analysis described an overall pooled prevalence of PsA of 20 percent in patients with psoriasis and 25 percent in the subset with moderate to severe psoriasis. […] Estimates of the prevalence of PsA among patients with psoriasis have ranged from 4 to 30 percent. […] Estimates of the prevalence of PsA among patients with psoriasis range from 14 to 31 percent. […] A prospective study of patients who presented with psoriasis but no arthritis, followed annually, found the annual incidence of PsA to be 2.7 to 3.2 percent.

• #23 The epidemiology and risk of mortality for patients with psoriatic arthritis

  https://psoriasis-hub.com/medical-information/the-epidemiology-and-risk-of-mortality-for-patients-with-psoriatic-arthritis

  In the general population, the prevalence of psoriatic arthritis (PsA) ranges from 0.1% to 1% worldwide. A high degree of variability has been observed between epidemiological studies, partly due to the geographic location and due to the use of different definitions of PsA. […] Most studies of prevalence trends of PsA have shown an increase in recent years. […] The prevalence of PsA in patients with psoriasis has been shown to be variable between continents: Asia, 14.0%; Africa, 15.5%; North America, 19.5%; South America, 21.5%; Europe, 22.7%. […] The incidence of PsA among patients with psoriasis is also varied, ranging from 1.7% to 7.4%. […] Evidence regarding the impact of PsA on mortality is conflicting, with the standardized mortality rate (SMR) varying from 0.05 to 98.5. […] Overall mortality does not appear to be increased in patients with PsA; however, there is an increase in certain cause-specific mortality groups such as cardiovascular comorbidities.

• #24 Clinical manifestations and diagnosis of psoriatic arthritis – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-psoriatic-arthritis

  Psoriatic arthritis (PsA) affects females and males equally, with an incidence of approximately 6 per 100,000 per year and a prevalence of approximately 1 to 2 per 1000 in the general population. […] A Canadian population study from 2019 reported the cumulative prevalence estimate for PsA of 0.17 percent, with an incidence of 15 per 100,000 population. […] A 2019 meta-analysis described an overall pooled prevalence of PsA of 20 percent in patients with psoriasis and 25 percent in the subset with moderate to severe psoriasis. […] Estimates of the prevalence of PsA among patients with psoriasis have ranged from 4 to 30 percent. […] Estimates of the prevalence of PsA among patients with psoriasis range from 14 to 31 percent. […] A prospective study of patients who presented with psoriasis but no arthritis, followed annually, found the annual incidence of PsA to be 2.7 to 3.2 percent.

• #25

  https://link.springer.com/article/10.1007/s13671-012-0032-8

  Psoriatic arthritis (PsA) is a chronic inflammatory disease that can be associated with permanent joint damage and disability. […] In this review, we address the epidemiology, natural history, and clinical characteristics of this disease, as well as available screening tools to provide dermatologists the information needed to identify patients with PsA. […] The mean age at onset of PsA is during approximately the fourth decade. PsA affects men and women approximately equally; the percentage of affected females ranged from 38.4 % to 60 % in the most recent studies. […] Previous studies from various parts of the world have suggested a wide variation in the incidence and prevalence of PsA in the general population. […] In these reviews, the incidence of PsA varied from 0.1 to 23 cases per 10^5 inhabitants (median 6.4 cases). Prevalence estimates varied from 1 case per 10^5 inhabitants in Japan to 420 cases per 10^5 inhabitants in Italy.

• #26 Psoriatic Arthritis: Practice Essentials, Background, Pathophysiology and Etiology

  https://emedicine.medscape.com/article/2196539-overview

  According to the National Psoriasis Foundation, psoriatic arthritis affects about 1 million people in the United States, or about 30% of all persons with psoriasis. However, prevalence rates vary widely among studies. In one population-based study, less than 10% of patients with psoriasis developed clinically recognized psoriatic arthritis during a 30-year period. A random telephone survey of 27,220 US residents found a 0.25% prevalence rate for psoriatic arthritis in the general population and an 11% prevalence rate in patients with psoriasis. However, the exact frequency of the disorder in patients with psoriasis remains uncertain, with the estimated rate ranging from 5-30%. […] […] Moreover, since the late 20th century, the incidence of psoriatic arthritis appears to have been rising in both men and women. Reasons for the increase are unknown; it may be related to a true change in incidence or to a greater overall awareness of the diagnosis by physicians. […]

• #27 Epidemiology of Psoriatic Arthritis: Who Gets It?

  https://www.webmd.com/arthritis/psoriatic-arthritis/who-gets-psoriatic-arthritis

  Germany, Italy, Sweden, and the United Kingdom appear to have the highest rates of the disorder among select industrialized countries. Information about the disease from Africa and other regions is largely unreliable. […] The disease is most common among adults, but you can have it in childhood. In adults, the condition generally appears between the ages of 30 and 50. […] It appears your genes and immune system may have something to do with it, but it could also be caused by external things, such as infections and injuries to joints and tendons. Among people with psoriasis, risk factors for the disease may include family history of the disorder, obesity, and smoking. […] Yes, particularly for cardiovascular conditions. […] Hypertension, diabetes, and obesity are among common heart disease and stroke risk factors that seem to develop after people are diagnosed with psoriatic arthritis, in part because of the chronic inflammation that comes with the disorder. But theres also evidence that many people with the condition already have those health issues together called comorbidities when they receive their diagnosis. […] Theres also research that suggests that people with psoriatic arthritis may be vulnerable to mental health and lung diseases.

• #28 Epidemiology of Psoriatic Arthritis: Who Gets It?

  https://www.webmd.com/arthritis/psoriatic-arthritis/who-gets-psoriatic-arthritis

  Germany, Italy, Sweden, and the United Kingdom appear to have the highest rates of the disorder among select industrialized countries. Information about the disease from Africa and other regions is largely unreliable. […] The disease is most common among adults, but you can have it in childhood. In adults, the condition generally appears between the ages of 30 and 50. […] It appears your genes and immune system may have something to do with it, but it could also be caused by external things, such as infections and injuries to joints and tendons. Among people with psoriasis, risk factors for the disease may include family history of the disorder, obesity, and smoking. […] Yes, particularly for cardiovascular conditions. […] Hypertension, diabetes, and obesity are among common heart disease and stroke risk factors that seem to develop after people are diagnosed with psoriatic arthritis, in part because of the chronic inflammation that comes with the disorder. But theres also evidence that many people with the condition already have those health issues together called comorbidities when they receive their diagnosis. […] Theres also research that suggests that people with psoriatic arthritis may be vulnerable to mental health and lung diseases.

• #29 Numbers of Incidence Stable in US Patients with Psoriatic Arthritis

  https://www.hcplive.com/view/numbers-incidence-stable-us-patients-with-psoriatic-arthritis

  The difference in incidence and prevalence estimates across different geographic regions could be due to different data collection periods, underdiagnoses (in Asia), or genetic and environmental differences, investigators wrote. […] Mortality rates from PsA was similar to general population, without a significant change over time. This data is consistent from population-based studies, including the 1970 1999 Olmsted Data and recent data from the United Kingdom in the Health Improvement Network, according to investigators.

• #30 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  Studies examining the prevalence of PsA among patients with psoriasis have found that underdiagnosis is common. […] PsA is a clinically heterogeneous disorder. […] Classification criteria are designed to create more homogenous populations for research. […] The CASPAR criteria are the most widely used criteria and their high sensitivity and specificity (both 90% or better in most studies but sensitivity as low as 77.3% in D’Angelo et al 2009) have been demonstrated in many settings including dermatology and rheumatology clinics, family practice clinics, and among early arthritis cohorts. […] Early PsA is generally considered within the first two years of symptom onset. […] Increasing evidence supports the early diagnosis and treatment of PsA in order to improve long term outcomes. […] Knowledge of risk factors for PsA and use of screening tools may improve recognition of PsA among patients with psoriasis.

• #31 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  Studies examining the prevalence of PsA among patients with psoriasis have found that underdiagnosis is common. […] PsA is a clinically heterogeneous disorder. […] Classification criteria are designed to create more homogenous populations for research. […] The CASPAR criteria are the most widely used criteria and their high sensitivity and specificity (both 90% or better in most studies but sensitivity as low as 77.3% in D’Angelo et al 2009) have been demonstrated in many settings including dermatology and rheumatology clinics, family practice clinics, and among early arthritis cohorts. […] Early PsA is generally considered within the first two years of symptom onset. […] Increasing evidence supports the early diagnosis and treatment of PsA in order to improve long term outcomes. […] Knowledge of risk factors for PsA and use of screening tools may improve recognition of PsA among patients with psoriasis.

• #32 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  Psoriatic arthritis (PsA) is a chronic, progressive inflammatory arthritis that is common among patients with psoriasis and may result in permanent joint damage and disability. […] We now know that PsA is a systemic inflammatory disorder with health consequences beyond joint function such as cardiovascular disease and similar outcomes to rheumatoid arthritis (RA) including the prevalence of erosions and joint destruction. […] Development of more uniformly accepted classification criteria in 2006 have allowed for more comparable populations among epidemiologic studies. […] In this review, we discuss current knowledge around the epidemiology of psoriatic arthritis including prevalence of disease characteristics, classification of adult and pediatric psoriatic arthritis, the importance of early diagnosis of PsA including methods for screening and knowledge regarding risk factors for the development of PsA.

• #33 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  Studies examining the prevalence of PsA among patients with psoriasis have found that underdiagnosis is common. […] PsA is a clinically heterogeneous disorder. […] Classification criteria are designed to create more homogenous populations for research. […] The CASPAR criteria are the most widely used criteria and their high sensitivity and specificity (both 90% or better in most studies but sensitivity as low as 77.3% in D’Angelo et al 2009) have been demonstrated in many settings including dermatology and rheumatology clinics, family practice clinics, and among early arthritis cohorts. […] Early PsA is generally considered within the first two years of symptom onset. […] Increasing evidence supports the early diagnosis and treatment of PsA in order to improve long term outcomes. […] Knowledge of risk factors for PsA and use of screening tools may improve recognition of PsA among patients with psoriasis.

• #34 Psoriatic arthritis — epidemiology, diagnosis and treatment – Medical Independent

  https://www.medicalindependent.ie/societies/isr/psoriatic-arthritis-epidemiology-diagnosis-and-treatment/

  The CASPAR criteria possess high levels of specificity (98.7 per cent) and sensitivity (91.4 per cent) for diagnosing PsA in clinical practice. […] The clinical manifestations of other inflammatory joint diseases, such as rheumatoid arthritis, gout, or osteoarthritis, can mimic those of PsA and as a result, it is imperative that differentiation is made as early as possible for correct treatment initiation. […] PsA is associated with many comorbidities that have compounding negative effects to patients health and wellbeing. PsA patients with high disease activity are more likely to develop type 2 diabetes and metabolic syndrome when compared to the general population.

• #35 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  Studies examining the prevalence of PsA among patients with psoriasis have found that underdiagnosis is common. […] PsA is a clinically heterogeneous disorder. […] Classification criteria are designed to create more homogenous populations for research. […] The CASPAR criteria are the most widely used criteria and their high sensitivity and specificity (both 90% or better in most studies but sensitivity as low as 77.3% in D’Angelo et al 2009) have been demonstrated in many settings including dermatology and rheumatology clinics, family practice clinics, and among early arthritis cohorts. […] Early PsA is generally considered within the first two years of symptom onset. […] Increasing evidence supports the early diagnosis and treatment of PsA in order to improve long term outcomes. […] Knowledge of risk factors for PsA and use of screening tools may improve recognition of PsA among patients with psoriasis.

• #36 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  Studies examining the prevalence of PsA among patients with psoriasis have found that underdiagnosis is common. […] PsA is a clinically heterogeneous disorder. […] Classification criteria are designed to create more homogenous populations for research. […] The CASPAR criteria are the most widely used criteria and their high sensitivity and specificity (both 90% or better in most studies but sensitivity as low as 77.3% in D’Angelo et al 2009) have been demonstrated in many settings including dermatology and rheumatology clinics, family practice clinics, and among early arthritis cohorts. […] Early PsA is generally considered within the first two years of symptom onset. […] Increasing evidence supports the early diagnosis and treatment of PsA in order to improve long term outcomes. […] Knowledge of risk factors for PsA and use of screening tools may improve recognition of PsA among patients with psoriasis.

• #37 The Epidemiology Psoriatic Arthritis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4610151/

  Studies examining the prevalence of PsA among patients with psoriasis have found that underdiagnosis is common. […] PsA is a clinically heterogeneous disorder. […] Classification criteria are designed to create more homogenous populations for research. […] The CASPAR criteria are the most widely used criteria and their high sensitivity and specificity (both 90% or better in most studies but sensitivity as low as 77.3% in D’Angelo et al 2009) have been demonstrated in many settings including dermatology and rheumatology clinics, family practice clinics, and among early arthritis cohorts. […] Early PsA is generally considered within the first two years of symptom onset. […] Increasing evidence supports the early diagnosis and treatment of PsA in order to improve long term outcomes. […] Knowledge of risk factors for PsA and use of screening tools may improve recognition of PsA among patients with psoriasis.

• #38 Psoriatic arthritis — epidemiology, diagnosis and treatment – Medical Independent

  https://www.medicalindependent.ie/societies/isr/psoriatic-arthritis-epidemiology-diagnosis-and-treatment/

  Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease of the joints and skin characterised by the presence of dactylitis, enthesitis, nail psoriasis and spondylitis. […] The prevalence of PsA varies somewhat in the literature. Rates are estimated to range from 0.05-to-2 per cent of the general population. In almost 70 per cent of patients, psoriasis precedes the onset of arthritis. PsA is uncommon in the Asian and black populations and unlike rheumatoid arthritis, which affects more females than males, PsA has a female-to-male ratio of 1:1.9. […] It has been reported that up to 47 per cent of PsA patients develop erosions within two years of symptom onset. For this reason, early diagnosis and initiation of disease-modifying anti-rheumatic medications (DMARDs) and/or biological agents is vital to ensure positive patient outcomes and decrease morbidity.

• #39

  https://link.springer.com/article/10.1007/s13671-012-0032-8

  Estimates of the prevalence of PsA among patients with psoriasis have varied from 6-39 %. […] The highest estimates of PsA among patients with psoriasis are generally derived from dermatology clinics, possibly due to the increased severity of psoriasis in the dermatology clinic relative to the general population. […] Risk factors for the development of PsA may help to identify patients with psoriasis who should be screened for PsA or watched carefully for the development of joint symptoms. […] Several noteworthy studies have addressed risk factors for PsA and have suggested that psoriasis severity, nail dystrophy, smoking, trauma, obesity, obesity at the age of 18 years, and prior glucocorticoid use are risk factors for PsA. […] Whereas dermatologists will have varying comfort in assessing for PsA, simple screening tools have been developed to help identify which patients should receive further evaluation for the diagnosis of PsA. […] Four screening tools have been developed to date: the Psoriasis Epidemiology Screening Tool (PEST), Toronto Psoriatic Arthritis Screening (ToPAS), Psoriasis and Arthritis Screening Questionnaire (PASQ), and Psoriatic Arthritis Screening and Evaluation (PASE). […] It is important to recognize that these screening questionnaires, while they can be helpful, have been found to have much lower sensitivity and specificity than those reported in the initial validation studies, particularly when applied among psoriasis patients without known PsA.

• #40

  https://link.springer.com/article/10.1007/s13671-012-0032-8

  Estimates of the prevalence of PsA among patients with psoriasis have varied from 6-39 %. […] The highest estimates of PsA among patients with psoriasis are generally derived from dermatology clinics, possibly due to the increased severity of psoriasis in the dermatology clinic relative to the general population. […] Risk factors for the development of PsA may help to identify patients with psoriasis who should be screened for PsA or watched carefully for the development of joint symptoms. […] Several noteworthy studies have addressed risk factors for PsA and have suggested that psoriasis severity, nail dystrophy, smoking, trauma, obesity, obesity at the age of 18 years, and prior glucocorticoid use are risk factors for PsA. […] Whereas dermatologists will have varying comfort in assessing for PsA, simple screening tools have been developed to help identify which patients should receive further evaluation for the diagnosis of PsA. […] Four screening tools have been developed to date: the Psoriasis Epidemiology Screening Tool (PEST), Toronto Psoriatic Arthritis Screening (ToPAS), Psoriasis and Arthritis Screening Questionnaire (PASQ), and Psoriatic Arthritis Screening and Evaluation (PASE). […] It is important to recognize that these screening questionnaires, while they can be helpful, have been found to have much lower sensitivity and specificity than those reported in the initial validation studies, particularly when applied among psoriasis patients without known PsA.

• #41 Psoriatic Arthritis: Practice Essentials, Background, Pathophysiology and Etiology

  https://emedicine.medscape.com/article/2196539-overview

  A systematic review and meta-analysis of 28 studies estimated that the global average prevalence of psoriatic arthritis is 133 per 100,000 population (95% confidence interval [CI], 107-164 per 100,000), and the incidence is 83 per 100,000 persons per year (95% CI, 41-167 per 100,000). A systematic review and meta-analysis of 266 studies concluded that worldwide, approximately one in four persons with psoriasis has psoriatic arthritis. However, the prevalence of psoriatic arthritis internationally ranges widely, depending on the population studied. A 2013 German study found the rate of psoriatic arthritis in patients with psoriasis to be 30.2%. […] […] In a prospective cohort study from Canada that involved psoriasis patients without arthritis at study entry, 51 of 464 patients developed psoriatic arthritis over the course of 8 years of follow-up. The annual incidence rate was 2.7 cases of psoriatic arthritis per 100 psoriasis patients. Baseline variables associated with the development of psoriatic arthritis in multivariate analysis included the following: severe psoriasis (relative risk [RR] 5.4, P = 0.006); low level of education (college/university vs. high school incomplete, RR 4.5, P = 0.005; high school education vs high school incomplete, RR 3.3, P = 0.049); use of retinoid medications (RR 3.4, P = 0.02). […]

• #42 What Is the Future of Psoriatic Arthritis Treatment?

  https://www.pharmacytimes.com/view/what-is-the-future-of-psoriatic-arthritis-treatment

  More than 8 million Americans live with psoriasis, and PsA affects between 15% and 30% of those individuals. […] A hereditary link also appears evident, as individuals who have a first-degree relative with the condition have a 40% greater chance of developing the disease. […] However, diagnosis is often delayed because of the generality of symptoms, and study results show that just 30% of patients receive a proper diagnosis within the first 6 months of symptom onset. […] The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-568. doi:10.1016/j.rdc.2015.07.001

• #43 Psoriatic Arthritis

  https://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/rheumatology/psoriatic-arthritis/

  Estimates of PsA prevalence in the general population vary from 0.3% to 1%, with a higher prevalence of 6% to 42% in patients with psoriasis. […] The prevalence of spondyloarthropathies, of which PsA is a subset, has been estimated at 1% to 2% of the population. Psoriatic arthritis is more common in those aged 30 to 50 years, and it occurs nearly equally in both sexes. Prevalence studies also suggest a geographic variation, with a higher incidence in people of Northern European descent and a lower incidence in those of Japanese descent. […] Genetic factors play a role, as evidenced by the presence of a strong familial association and links with several major histocompatibility complex (MHC) class I alleles. Up to 40% of patients with PsA have a positive family history of psoriasis or arthritis.

• #44

  https://link.springer.com/article/10.1007/s13671-012-0032-8

  Estimates of the prevalence of PsA among patients with psoriasis have varied from 6-39 %. […] The highest estimates of PsA among patients with psoriasis are generally derived from dermatology clinics, possibly due to the increased severity of psoriasis in the dermatology clinic relative to the general population. […] Risk factors for the development of PsA may help to identify patients with psoriasis who should be screened for PsA or watched carefully for the development of joint symptoms. […] Several noteworthy studies have addressed risk factors for PsA and have suggested that psoriasis severity, nail dystrophy, smoking, trauma, obesity, obesity at the age of 18 years, and prior glucocorticoid use are risk factors for PsA. […] Whereas dermatologists will have varying comfort in assessing for PsA, simple screening tools have been developed to help identify which patients should receive further evaluation for the diagnosis of PsA. […] Four screening tools have been developed to date: the Psoriasis Epidemiology Screening Tool (PEST), Toronto Psoriatic Arthritis Screening (ToPAS), Psoriasis and Arthritis Screening Questionnaire (PASQ), and Psoriatic Arthritis Screening and Evaluation (PASE). […] It is important to recognize that these screening questionnaires, while they can be helpful, have been found to have much lower sensitivity and specificity than those reported in the initial validation studies, particularly when applied among psoriasis patients without known PsA.

• #45

  https://link.springer.com/article/10.1007/s13671-012-0032-8

  Estimates of the prevalence of PsA among patients with psoriasis have varied from 6-39 %. […] The highest estimates of PsA among patients with psoriasis are generally derived from dermatology clinics, possibly due to the increased severity of psoriasis in the dermatology clinic relative to the general population. […] Risk factors for the development of PsA may help to identify patients with psoriasis who should be screened for PsA or watched carefully for the development of joint symptoms. […] Several noteworthy studies have addressed risk factors for PsA and have suggested that psoriasis severity, nail dystrophy, smoking, trauma, obesity, obesity at the age of 18 years, and prior glucocorticoid use are risk factors for PsA. […] Whereas dermatologists will have varying comfort in assessing for PsA, simple screening tools have been developed to help identify which patients should receive further evaluation for the diagnosis of PsA. […] Four screening tools have been developed to date: the Psoriasis Epidemiology Screening Tool (PEST), Toronto Psoriatic Arthritis Screening (ToPAS), Psoriasis and Arthritis Screening Questionnaire (PASQ), and Psoriatic Arthritis Screening and Evaluation (PASE). […] It is important to recognize that these screening questionnaires, while they can be helpful, have been found to have much lower sensitivity and specificity than those reported in the initial validation studies, particularly when applied among psoriasis patients without known PsA.

• #46 Screen for PsA

  https://www.psoriasis.org/psoriatic-arthritis-screening-test/

  Psoriatic arthritis (PsA) is a common comorbidity of psoriasis. PsA can lead to permanent damage to bones and joints, especially if untreated. Currently, no diagnostic test for PsA exists. Thankfully, validated screening tools exist to help identify signs and symptoms of the disease. […] One in three individuals with psoriasis have PsA. […] The Psoriasis Epidemiology Screening Tool (PEST) is a validated screening tool for psoriatic arthritis. It is recommended that individuals with psoriasis complete the PEST every six months. Forty-one percent of those who screened positive for PsA using the PEST had not previously been diagnosed with PsA.

• #47 Psoriasis epidemiology screening tool (PEST) is useful for the detection of psoriatic arthritis in the Japanese population | Scientific Reports

  https://www.nature.com/articles/s41598-021-95620-4

  Psoriasis is a chronic inflammatory skin disease that involves various systemic organs and tissues and is characterized by scaly erythematous skin. Among the different types of psoriasis, psoriatic arthritis (PsA) is frequently reported, and occasionally develops into severe arthritis leading to joint dysfunction. […] In this study, we investigated the utility of a representative tool, the psoriasis epidemiology screening tool (PEST) questionnaire, to identify PsA among Japanese patients with psoriasis. […] The frequency of PsA was significantly increased in patients with PEST scores3, with a sensitivity of 93.1% and a specificity of 78.9%. […] Our study proposes that the PEST questionnaire might be a useful tool to detect PsA in the Japanese population. […] Although the usefulness of the PEST questionnaire to detect PsA has been validated in some Asian countries, it remains unclear whether it can be used for the Japanese population.

• #48 Psoriasis epidemiology screening tool (PEST) is useful for the detection of psoriatic arthritis in the Japanese population | Scientific Reports

  https://www.nature.com/articles/s41598-021-95620-4

  Our study showed a relatively high sensitivity and specificity in the PEST questionnaire. […] Therefore, these features might contribute to the increasing quality of the PEST questionnaire in the Japanese population, suggesting that this questionnaire might be eligible for the Asian population to identify PsA among psoriasis patients. […] To clarify the precise prevalence in the Japanese PsA population, a large investigation will be required in the future. […] Our results suggest a possible higher prevalence of PsA than previously thought.

• #49

  https://link.springer.com/article/10.1007/s13671-012-0032-8

  Estimates of the prevalence of PsA among patients with psoriasis have varied from 6-39 %. […] The highest estimates of PsA among patients with psoriasis are generally derived from dermatology clinics, possibly due to the increased severity of psoriasis in the dermatology clinic relative to the general population. […] Risk factors for the development of PsA may help to identify patients with psoriasis who should be screened for PsA or watched carefully for the development of joint symptoms. […] Several noteworthy studies have addressed risk factors for PsA and have suggested that psoriasis severity, nail dystrophy, smoking, trauma, obesity, obesity at the age of 18 years, and prior glucocorticoid use are risk factors for PsA. […] Whereas dermatologists will have varying comfort in assessing for PsA, simple screening tools have been developed to help identify which patients should receive further evaluation for the diagnosis of PsA. […] Four screening tools have been developed to date: the Psoriasis Epidemiology Screening Tool (PEST), Toronto Psoriatic Arthritis Screening (ToPAS), Psoriasis and Arthritis Screening Questionnaire (PASQ), and Psoriatic Arthritis Screening and Evaluation (PASE). […] It is important to recognize that these screening questionnaires, while they can be helpful, have been found to have much lower sensitivity and specificity than those reported in the initial validation studies, particularly when applied among psoriasis patients without known PsA.

• #50 The epidemiology and risk of mortality for patients with psoriatic arthritis

  https://psoriasis-hub.com/medical-information/the-epidemiology-and-risk-of-mortality-for-patients-with-psoriatic-arthritis

  In the general population, the prevalence of psoriatic arthritis (PsA) ranges from 0.1% to 1% worldwide. A high degree of variability has been observed between epidemiological studies, partly due to the geographic location and due to the use of different definitions of PsA. […] Most studies of prevalence trends of PsA have shown an increase in recent years. […] The prevalence of PsA in patients with psoriasis has been shown to be variable between continents: Asia, 14.0%; Africa, 15.5%; North America, 19.5%; South America, 21.5%; Europe, 22.7%. […] The incidence of PsA among patients with psoriasis is also varied, ranging from 1.7% to 7.4%. […] Evidence regarding the impact of PsA on mortality is conflicting, with the standardized mortality rate (SMR) varying from 0.05 to 98.5. […] Overall mortality does not appear to be increased in patients with PsA; however, there is an increase in certain cause-specific mortality groups such as cardiovascular comorbidities.

• #51 The epidemiology and risk of mortality for patients with psoriatic arthritis

  https://psoriasis-hub.com/medical-information/the-epidemiology-and-risk-of-mortality-for-patients-with-psoriatic-arthritis

  In the general population, the prevalence of psoriatic arthritis (PsA) ranges from 0.1% to 1% worldwide. A high degree of variability has been observed between epidemiological studies, partly due to the geographic location and due to the use of different definitions of PsA. […] Most studies of prevalence trends of PsA have shown an increase in recent years. […] The prevalence of PsA in patients with psoriasis has been shown to be variable between continents: Asia, 14.0%; Africa, 15.5%; North America, 19.5%; South America, 21.5%; Europe, 22.7%. […] The incidence of PsA among patients with psoriasis is also varied, ranging from 1.7% to 7.4%. […] Evidence regarding the impact of PsA on mortality is conflicting, with the standardized mortality rate (SMR) varying from 0.05 to 98.5. […] Overall mortality does not appear to be increased in patients with PsA; however, there is an increase in certain cause-specific mortality groups such as cardiovascular comorbidities.

• #52 Psoriatic arthritis — epidemiology, diagnosis and treatment – Medical Independent

  https://www.medicalindependent.ie/societies/isr/psoriatic-arthritis-epidemiology-diagnosis-and-treatment/

  The CASPAR criteria possess high levels of specificity (98.7 per cent) and sensitivity (91.4 per cent) for diagnosing PsA in clinical practice. […] The clinical manifestations of other inflammatory joint diseases, such as rheumatoid arthritis, gout, or osteoarthritis, can mimic those of PsA and as a result, it is imperative that differentiation is made as early as possible for correct treatment initiation. […] PsA is associated with many comorbidities that have compounding negative effects to patients health and wellbeing. PsA patients with high disease activity are more likely to develop type 2 diabetes and metabolic syndrome when compared to the general population.

• #53 Psoriatic arthritis: the joint and beyond | Medicine Today

  https://medicinetoday.com.au/mt/2020/january/feature-article/psoriatic-arthritis-joint-and-beyond

  Estimates of the prevalence of PsA range from 0.001% to 0.43%. PsA has been reported in about 30% of patients with psoriasis. In contrast to the female predominance seen in rheumatoid arthritis, PsA is equally prevalent in both sexes. The onset of PsA often occurs between the ages of 30 and 50 years, but juvenile PsA also does occur. […] In a study from the Australian Rheumatology Association Database, 57.8% of participants reported having two or more comorbidities, with hypertension (38.2%) and depression (35.9%) the most common. In the University of Toronto PsA Clinic, 42.2% of patients had three or more comorbidities. Increased comorbidity is also associated with a poorer response to disease-modifying therapy in patients with PsA. […] In a 2017 meta-analysis, patients with PsA had a 43% increased risk of cardiovascular events, including angina, ischaemic heart disease, coronary artery disease or myocardial infarction, compared with the general population.

• #54 Psoriatic arthritis: the joint and beyond | Medicine Today

  https://medicinetoday.com.au/mt/2020/january/feature-article/psoriatic-arthritis-joint-and-beyond

  Estimates of the prevalence of PsA range from 0.001% to 0.43%. PsA has been reported in about 30% of patients with psoriasis. In contrast to the female predominance seen in rheumatoid arthritis, PsA is equally prevalent in both sexes. The onset of PsA often occurs between the ages of 30 and 50 years, but juvenile PsA also does occur. […] In a study from the Australian Rheumatology Association Database, 57.8% of participants reported having two or more comorbidities, with hypertension (38.2%) and depression (35.9%) the most common. In the University of Toronto PsA Clinic, 42.2% of patients had three or more comorbidities. Increased comorbidity is also associated with a poorer response to disease-modifying therapy in patients with PsA. […] In a 2017 meta-analysis, patients with PsA had a 43% increased risk of cardiovascular events, including angina, ischaemic heart disease, coronary artery disease or myocardial infarction, compared with the general population.

• #55 Psoriatic arthritis: the joint and beyond | Medicine Today

  https://medicinetoday.com.au/mt/2020/january/feature-article/psoriatic-arthritis-joint-and-beyond

  Estimates of the prevalence of PsA range from 0.001% to 0.43%. PsA has been reported in about 30% of patients with psoriasis. In contrast to the female predominance seen in rheumatoid arthritis, PsA is equally prevalent in both sexes. The onset of PsA often occurs between the ages of 30 and 50 years, but juvenile PsA also does occur. […] In a study from the Australian Rheumatology Association Database, 57.8% of participants reported having two or more comorbidities, with hypertension (38.2%) and depression (35.9%) the most common. In the University of Toronto PsA Clinic, 42.2% of patients had three or more comorbidities. Increased comorbidity is also associated with a poorer response to disease-modifying therapy in patients with PsA. […] In a 2017 meta-analysis, patients with PsA had a 43% increased risk of cardiovascular events, including angina, ischaemic heart disease, coronary artery disease or myocardial infarction, compared with the general population.

• #56 Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study | Nature Reviews Rheumatology

  https://www.nature.com/articles/s41584-021-00578-2

  The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. […] PsA can lead to joint erosions and deformities, as well as to decreased quality of life, high levels of psychosocial stress and increased rates of comorbidities, unemployment, absenteeism and productivity loss. […] Despite this burden, PsA remains both underdiagnosed and undertreated, even within dermatology practices. […] The current challenges in diagnosing and treating PsA produce a considerable gap in the care of patients with psoriatic disease, given that a delay in treatment of as little as 6 months can lead to worse disease outcomes. […] Highly effective treatment strategies are a major unmet need in PsA, and various interventions have been envisioned, including innovative therapeutic targets, combination therapies or potentially preventive measures.

• #57 Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study | Nature Reviews Rheumatology

  https://www.nature.com/articles/s41584-021-00578-2

  The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. […] PsA can lead to joint erosions and deformities, as well as to decreased quality of life, high levels of psychosocial stress and increased rates of comorbidities, unemployment, absenteeism and productivity loss. […] Despite this burden, PsA remains both underdiagnosed and undertreated, even within dermatology practices. […] The current challenges in diagnosing and treating PsA produce a considerable gap in the care of patients with psoriatic disease, given that a delay in treatment of as little as 6 months can lead to worse disease outcomes. […] Highly effective treatment strategies are a major unmet need in PsA, and various interventions have been envisioned, including innovative therapeutic targets, combination therapies or potentially preventive measures.

• #58 Psoriatic Arthritis: Practice Essentials, Background, Pathophysiology and Etiology

  https://emedicine.medscape.com/article/2196539-overview

  There is a high prevalence of previously undiagnosed active psoriatic arthritis among patients with psoriasis who are seen by dermatologists. In a 2009 prospective German study, of 1511 patients with plaque-type psoriasis, 20.6% were found to have psoriatic arthritis, with 85% of the cases having been previously undiagnosed. […] […] The number of diagnosed cases of psoriasis and psoriatic arthritis has risen dramatically in sub-Saharan Africa in association with the area’s escalating epidemic of HIV infection. Although HIV is not known to affect the incidence of psoriasis, it may significantly exacerbate otherwise limited disease. The evolution of mild psoriasis to erythroderma in the setting of a flare-up of psoriatic arthritis may be a sign of HIV infection.

• #59 Psoriasis and Psoriatic Arthritis Overview

  https://www.ajmc.com/view/psoriasis-and-psoriatic-arthritis-overview

  PsA is an underdiagnosed and undertreated inflammatory joint disease that develops in a substantial minority of patients with psoriasis. […] Among patients with psoriasis, the prevalence of PsA in recent US cohort studies ranged from 22% to 27%. […] Overall, PsA affects approximately 0.1% to 0.2% of the general population. […] The clinical manifestations of PsA tend to emerge 5-12 years after initial skin presentation (ie, between the ages of 30 and 50 years in affected individuals). […] One of the major barriers to improved prognosis involves widespread undertreatment. […] Many patients with PsA do not receive the recommended systemic therapies to slow disease progression. […] In the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey (N = 1005), only half of patients were being treated with conventional oral therapy (24%) or biologic therapy (26%) to address their joint symptoms. […] To minimize the delay in diagnosing PsA, dermatologists are encouraged to screen patients with psoriasis for the signs and symptoms of PsA at every clinic visit. […] The prevalence of undiagnosed PsA among patients with psoriasis (N = 7831) was 15.5%.

• #60 Psoriasis and Psoriatic Arthritis Overview

  https://www.ajmc.com/view/psoriasis-and-psoriatic-arthritis-overview

  PsA is an underdiagnosed and undertreated inflammatory joint disease that develops in a substantial minority of patients with psoriasis. […] Among patients with psoriasis, the prevalence of PsA in recent US cohort studies ranged from 22% to 27%. […] Overall, PsA affects approximately 0.1% to 0.2% of the general population. […] The clinical manifestations of PsA tend to emerge 5-12 years after initial skin presentation (ie, between the ages of 30 and 50 years in affected individuals). […] One of the major barriers to improved prognosis involves widespread undertreatment. […] Many patients with PsA do not receive the recommended systemic therapies to slow disease progression. […] In the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey (N = 1005), only half of patients were being treated with conventional oral therapy (24%) or biologic therapy (26%) to address their joint symptoms. […] To minimize the delay in diagnosing PsA, dermatologists are encouraged to screen patients with psoriasis for the signs and symptoms of PsA at every clinic visit. […] The prevalence of undiagnosed PsA among patients with psoriasis (N = 7831) was 15.5%.

• #61 What Is the Future of Psoriatic Arthritis Treatment?

  https://www.pharmacytimes.com/view/what-is-the-future-of-psoriatic-arthritis-treatment

  More than 8 million Americans live with psoriasis, and PsA affects between 15% and 30% of those individuals. […] A hereditary link also appears evident, as individuals who have a first-degree relative with the condition have a 40% greater chance of developing the disease. […] However, diagnosis is often delayed because of the generality of symptoms, and study results show that just 30% of patients receive a proper diagnosis within the first 6 months of symptom onset. […] The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-568. doi:10.1016/j.rdc.2015.07.001

• #62 Epidemiological trends in psoriatic arthritis: a comprehensive population-based study | Arthritis Research & Therapy | Full Text

  https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-024-03339-0

  The reported prevalence of PsA worldwide ranges from 0.1 to 1% in the general population. […] Most investigations into PsA prevalence trends indicate a rise in prevalence in recent years, whereas fewer studies addressing incidence trends over time yield inconsistent findings. […] The objectives of our study encompassed estimating the temporal trends in PsA prevalence and incidence, as well as assessing variations among different age, gender, and ethnic subgroups in the general population of Israel spanning from 2016 to 2022. […] The crude prevalence of PsA has increased during the study period, from 0.165% in 2016 to 0.221% in 2022 and compared to 2006, it had tripled. […] The prevalence of PsA was associated with several demographic and lifestyle factors. […] Our study demonstrates an increasing trend in the crude and age-adjusted prevalence and incidence of PsA over the study period.

• #63 Time Trends in Epidemiology and Characteristics of Psoriatic Arthritis Over 3 Decades: A Population-based Study | The Journal of Rheumatology

  https://www.jrheum.org/content/36/2/361

  Objective. To determine time trends in incidence, prevalence, and clinical characteristics of psoriatic arthritis (PsA) over a 30-year period. […] The overall age- and sex-adjusted annual incidence of PsA per 100,000 was 7.2 with a higher incidence in men (9.1) than women (5.4). The age- and sex-adjusted incidence of PsA per 100,000 increased from 3.6 between 1970 and 1979 to 9.8 between 1990 and 2000 (p for trend 0.001). […] The overall, estimated point prevalence of PsA on January 1, 2000, was 158 per 100,000. […] Our findings indicate that the incidence of PsA has been rising over 30 years in men and women.

• #64

  https://link.springer.com/article/10.1007/s00296-020-04734-x

  Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis, usually seronegative and associated with psoriasis (Ps). The prevalence and incidence of psoriatic arthritis show strong ethnic and geographic variations. The aim of the study was to assess the epidemiological trends in psoriatic arthritis in Poland. A steady increase in the number of PsA patients (from 16,790 to 32,644) and in PsA recorded prevalence (from 38.47 per 100,000 in 2008 to 73.11 per 100,000 in 2018) was observed between 2008 and 2018. The PsA/Ps ratio increased to a similar extent (from 8.3 to 17.5%). The study showed a steady and continuous increase in PsA recorded prevalence. A simultaneous increase in the PsA/Ps ratio suggests that the main reason for the observed trend is greater disease detection. […] Although the prevalence and incidence of PsA show strong ethnic and geographic variations substantial differences are also seen between studies conducted in same populations. This large heterogeneity of epidemiological data is due to several factors, including lack of uniform diagnostic criteria, different study period (several studies show substantial temporal changes in PsA epidemiology), different study design (population-based studies or hospital/clinic-based reports; general population or specific groups, e.g. adults etc.) and different case definitions (e.g. self-reporting, experts diagnosis, analysis of healthcare system databases etc.).

• #65 Numbers of Incidence Stable in US Patients with Psoriatic Arthritis

  https://www.hcplive.com/view/numbers-incidence-stable-us-patients-with-psoriatic-arthritis

  A recent study finds increasing number of women with PsA, but an overall stable incidence of disease compared to previous studies in same population. […] A recent study identified a stable incidence in the trend of patients with psoriatic arthritis (PsA) in a US patient population since 2000. […] The annual incidence of PsA per 100,000 population was 8.5 (95% CI, 5.9 9.4) in the data compiled from 2000 to 2017. […] The point prevalence of PsA as recently as 2015 was 181.8 per 100,000 (95% CI, 156.5 – 207.1). […] Incidence rate data remained relatively stable during 2000 2017 with no increase in males. […] Data showed the increase in females at 3% per year from 2000 to 2017, compared to a 4% annual rise in incidence from 1970 to 1999. […] Geographic regions were also used in comparison for the PsA rates. Investigators wrote the study results for the United States were consistent with those reported in a recent meta-analysis showing 8.26 PsA cases per 100,000 people.

• #66

  https://link.springer.com/article/10.1007/s00296-020-04734-x

  The actual PsA prevalence is difficult to estimate as the results of epidemiological studies vary widely. This heterogeneity is due to number of factors, e.g. differences in methodology, target populations and criteria used to define PsA. […] Our study showed a steady increase of PsA between 2008 and 2018. This finding is not surprising as previous studies showed similar results. This time trend may be related to a true increase in disease expression. However, a more plausible explanation is the greater detectability of the disease resulting from an increasing awareness among physicians to detect PsA as early as possible and more sensitive diagnostic methods. […] Our study showed a rising PsA/Ps ratioit increased from 0.083 in 2008 to 0.175 in 2018. As mentioned above, these results suggest an improving detection of PsA. Prevalence of PsA has been reported to be in a wide range among patients with psoriasis (5.840.9%).

• #67 Epidemiology of Psoriatic Arthritis: Who Gets It?

  https://www.webmd.com/arthritis/psoriatic-arthritis/who-gets-psoriatic-arthritis

  Germany, Italy, Sweden, and the United Kingdom appear to have the highest rates of the disorder among select industrialized countries. Information about the disease from Africa and other regions is largely unreliable. […] The disease is most common among adults, but you can have it in childhood. In adults, the condition generally appears between the ages of 30 and 50. […] It appears your genes and immune system may have something to do with it, but it could also be caused by external things, such as infections and injuries to joints and tendons. Among people with psoriasis, risk factors for the disease may include family history of the disorder, obesity, and smoking. […] Yes, particularly for cardiovascular conditions. […] Hypertension, diabetes, and obesity are among common heart disease and stroke risk factors that seem to develop after people are diagnosed with psoriatic arthritis, in part because of the chronic inflammation that comes with the disorder. But theres also evidence that many people with the condition already have those health issues together called comorbidities when they receive their diagnosis. […] Theres also research that suggests that people with psoriatic arthritis may be vulnerable to mental health and lung diseases.

• #68 National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES] – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/national-prevalence-of-psoriatic-arthritis-in-the-united-states-data-from-national-health-and-nutrition-examination-survey-nhanes/

  This population-based cross-sectional study suggests that PsA is a relatively common inflammatory arthritis affecting 0.41% of the US adult population. […] Similar to prior studies, the prevalence of PsA was highest in the age category 50-59 years, with decrease in prevalence in the older population. […] To more accurately estimate PsA prevalence, future NHANES research efforts may consider PsA screening questionnaires for psoriasis patients and an in-person rheumatologist examination.

• #69 Psoriatic juvenile idiopathic arthritis: Epidemiology, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/psoriatic-juvenile-idiopathic-arthritis-epidemiology-clinical-manifestations-and-diagnosis

  Psoriatic juvenile idiopathic arthritis (psJIA), or alternately juvenile psoriatic arthritis (JPsA), is a condition that can range widely in presentation and severity. […] The epidemiology, clinical manifestations, and diagnosis of psJIA are discussed here. […] The prevalence of psJIA is not known with certainty, and there appears to be considerable geographic variation. […] psJIA represents approximately 7 percent (range: 0 to 11 percent) of all patients with JIA in series that include only patients with frank psoriasis or using International League of Associations for Rheumatology (ILAR) criteria. […] Series employing the more inclusive Vancouver criteria suggest that psJIA represents 8 to 20 percent of JIA. […] The incidence and prevalence of psJIA among children with psoriasis are not defined.

• #70 Psoriatic juvenile idiopathic arthritis: Epidemiology, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/psoriatic-juvenile-idiopathic-arthritis-epidemiology-clinical-manifestations-and-diagnosis

  In the pediatric population, the age at onset of psJIA is bimodal. […] A first peak (mainly in females) occurs during the preschool years and bears clinical similarity to early-onset oligoarticular JIA. […] The second peak is seen during middle to late childhood and resembles adult psoriatic arthritis.

• #71 Psoriatic arthritis | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/psoriatic-arthritis?lang=us

  Overall prevalence is ~0.5% (range 0.1-1%), however, it affects up to ~25% (range 6-41%) of patients with psoriasis. […] In contrast to many other arthropathies, there is no gender predilection in psoriatic arthritis. The median age of diagnosis is 48 years.

• #72 Psoriatic arthritis | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/psoriatic-arthritis?lang=us

  Overall prevalence is ~0.5% (range 0.1-1%), however, it affects up to ~25% (range 6-41%) of patients with psoriasis. […] In contrast to many other arthropathies, there is no gender predilection in psoriatic arthritis. The median age of diagnosis is 48 years.

• #73 Psoriatic arthritis: the joint and beyond | Medicine Today

  https://medicinetoday.com.au/mt/2020/january/feature-article/psoriatic-arthritis-joint-and-beyond

  Estimates of the prevalence of PsA range from 0.001% to 0.43%. PsA has been reported in about 30% of patients with psoriasis. In contrast to the female predominance seen in rheumatoid arthritis, PsA is equally prevalent in both sexes. The onset of PsA often occurs between the ages of 30 and 50 years, but juvenile PsA also does occur. […] In a study from the Australian Rheumatology Association Database, 57.8% of participants reported having two or more comorbidities, with hypertension (38.2%) and depression (35.9%) the most common. In the University of Toronto PsA Clinic, 42.2% of patients had three or more comorbidities. Increased comorbidity is also associated with a poorer response to disease-modifying therapy in patients with PsA. […] In a 2017 meta-analysis, patients with PsA had a 43% increased risk of cardiovascular events, including angina, ischaemic heart disease, coronary artery disease or myocardial infarction, compared with the general population.

• #74 Frontiers | Prevalence of psoriatic arthritis in Italy: insights from the multicentric MAPSI study

  https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1484988/full

  The MAnagement of PSoriatic Arthritis in Italy (MAPSI) project is a multicenter observational study aimed to investigate the prevalence of PsA and characteristics in an Italian cohort. This study included 454 patients diagnosed or confirmed by a rheumatologist across 25 Rheumatology Units in Italy. Data were collected on demographics, clinical features, and treatment histories. In our cohort, distinct gender differences were observed in PsA phenotype and disease impact. […] Worldwide, PsA represents around 20% of cases referred to early arthritis clinics, constituting a real challenge from the point of view of diagnosis and management. Early diagnosis is essential to prevent long-term functional disability and to ensure optimal management of arthritis and its key comorbidities. […] Although classification criteria for PsA are widely accepted, the lack of specific diagnostic criteria can lead to delayed diagnoses, with many patients experiencing diagnostic delays exceeding 1 year. This contributes to uncertain prevalence of PsA.

• #75 Frontiers | Prevalence of psoriatic arthritis in Italy: insights from the multicentric MAPSI study

  https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1484988/full

  Overall, this cross-sectional analysis indicates that peripheral arthritis is the most prevalent PsA phenotype in this Italian cohort, with notable gender-specific variations in axial and enthesitic involvement. Additionally, the observed delays in diagnosis for a significant proportion of patients underscore the need for improved awareness and screening practices in PsA. The identified prevalence of smoking among male patients and the increased skin severity in males highlight potential areas for targeted interventions. […] In summary, while the exact prevalence of PsA has been less extensively studied compared to many other rheumatic diseases, our study provides valuable real-world data on Italian patients affected by PsA, offering key insights into the patient characteristics that can inform effective treatment strategies. We found that, although the prevalence of PsA is balanced between genders, significant gender-specific differences exist in clinical manifestation. These findings underscore the importance of a gender-sensitive approach to the management and assessment of PsA, highlighting the need for tailored interventions to address the unique clinical presentations and comorbidity profiles in each gender. Further longitudinal research is essential to understand how these gender-based differences impact long-term disease progression and treatment outcomes.

• #76 Numbers of Incidence Stable in US Patients with Psoriatic Arthritis

  https://www.hcplive.com/view/numbers-incidence-stable-us-patients-with-psoriatic-arthritis

  A recent study finds increasing number of women with PsA, but an overall stable incidence of disease compared to previous studies in same population. […] A recent study identified a stable incidence in the trend of patients with psoriatic arthritis (PsA) in a US patient population since 2000. […] The annual incidence of PsA per 100,000 population was 8.5 (95% CI, 5.9 9.4) in the data compiled from 2000 to 2017. […] The point prevalence of PsA as recently as 2015 was 181.8 per 100,000 (95% CI, 156.5 – 207.1). […] Incidence rate data remained relatively stable during 2000 2017 with no increase in males. […] Data showed the increase in females at 3% per year from 2000 to 2017, compared to a 4% annual rise in incidence from 1970 to 1999. […] Geographic regions were also used in comparison for the PsA rates. Investigators wrote the study results for the United States were consistent with those reported in a recent meta-analysis showing 8.26 PsA cases per 100,000 people.

• #77

  https://link.springer.com/article/10.1007/s00296-020-04734-x

  The actual PsA prevalence is difficult to estimate as the results of epidemiological studies vary widely. This heterogeneity is due to number of factors, e.g. differences in methodology, target populations and criteria used to define PsA. […] Our study showed a steady increase of PsA between 2008 and 2018. This finding is not surprising as previous studies showed similar results. This time trend may be related to a true increase in disease expression. However, a more plausible explanation is the greater detectability of the disease resulting from an increasing awareness among physicians to detect PsA as early as possible and more sensitive diagnostic methods. […] Our study showed a rising PsA/Ps ratioit increased from 0.083 in 2008 to 0.175 in 2018. As mentioned above, these results suggest an improving detection of PsA. Prevalence of PsA has been reported to be in a wide range among patients with psoriasis (5.840.9%).

• #78

  https://link.springer.com/article/10.1007/s00296-020-04734-x

  Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis, usually seronegative and associated with psoriasis (Ps). The prevalence and incidence of psoriatic arthritis show strong ethnic and geographic variations. The aim of the study was to assess the epidemiological trends in psoriatic arthritis in Poland. A steady increase in the number of PsA patients (from 16,790 to 32,644) and in PsA recorded prevalence (from 38.47 per 100,000 in 2008 to 73.11 per 100,000 in 2018) was observed between 2008 and 2018. The PsA/Ps ratio increased to a similar extent (from 8.3 to 17.5%). The study showed a steady and continuous increase in PsA recorded prevalence. A simultaneous increase in the PsA/Ps ratio suggests that the main reason for the observed trend is greater disease detection. […] Although the prevalence and incidence of PsA show strong ethnic and geographic variations substantial differences are also seen between studies conducted in same populations. This large heterogeneity of epidemiological data is due to several factors, including lack of uniform diagnostic criteria, different study period (several studies show substantial temporal changes in PsA epidemiology), different study design (population-based studies or hospital/clinic-based reports; general population or specific groups, e.g. adults etc.) and different case definitions (e.g. self-reporting, experts diagnosis, analysis of healthcare system databases etc.).

• #79

  https://link.springer.com/article/10.1007/s00296-020-04734-x

  Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis, usually seronegative and associated with psoriasis (Ps). The prevalence and incidence of psoriatic arthritis show strong ethnic and geographic variations. The aim of the study was to assess the epidemiological trends in psoriatic arthritis in Poland. A steady increase in the number of PsA patients (from 16,790 to 32,644) and in PsA recorded prevalence (from 38.47 per 100,000 in 2008 to 73.11 per 100,000 in 2018) was observed between 2008 and 2018. The PsA/Ps ratio increased to a similar extent (from 8.3 to 17.5%). The study showed a steady and continuous increase in PsA recorded prevalence. A simultaneous increase in the PsA/Ps ratio suggests that the main reason for the observed trend is greater disease detection. […] Although the prevalence and incidence of PsA show strong ethnic and geographic variations substantial differences are also seen between studies conducted in same populations. This large heterogeneity of epidemiological data is due to several factors, including lack of uniform diagnostic criteria, different study period (several studies show substantial temporal changes in PsA epidemiology), different study design (population-based studies or hospital/clinic-based reports; general population or specific groups, e.g. adults etc.) and different case definitions (e.g. self-reporting, experts diagnosis, analysis of healthcare system databases etc.).

• #80

  https://link.springer.com/article/10.1007/s00296-020-04734-x

  Although the results of our study indicate an improving detection of PsA, still many cases of the disease (possibly up to 50%) remain undiagnosed. This points to the need of development of the new diagnostic tools and criteria on the one hand and of increasing the awareness of PsA among patients and physicians (especially general practitioners) on the other hand.

• #81 National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES] – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/national-prevalence-of-psoriatic-arthritis-in-the-united-states-data-from-national-health-and-nutrition-examination-survey-nhanes/

  National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES] […] Psoriatic arthritis (PsA) is a chronic inflammatory disease which significantly impacts quality of life and healthcare costs. […] Understanding PsA prevalence at a national level is fundamental for comprehensively assessing the disease burden, identifying populations at high risk for PsA development, and informing critical healthcare policy decisions. […] The objective of our study was to provide national PsA prevalence estimates and query potential associated factors within the US population using the National Health and Nutrition Examination Survey (NHANES). […] Of the estimated 225,557,413 participants aged 20 years or above, 912,292 adults (0.41%) reported a diagnosis of PsA.

Zobacz więcej